Crinetics Pharmaceuticals Inc (CRNX)

$45.05

+1.23

(+2.81%)

Market is closed - opens 7 PM, 02 May 2024

Insights on Crinetics Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.67M → 346.0K (in $), with an average decrease of 64.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 6 quarters, -40.39M → -60.09M (in $), with an average decrease of 8.4% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.0% return, outperforming this stock by 93.9%

Performance

  • $43.66
    $45.88
    $45.05
    downward going graph

    3.07%

    Downside

    Day's Volatility :4.83%

    Upside

    1.81%

    downward going graph
  • $15.76
    $49.58
    $45.05
    downward going graph

    65.02%

    Downside

    52 Weeks Volatility :68.21%

    Upside

    9.14%

    downward going graph

Returns

PeriodCrinetics Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
17.76%
-1.3%
0.0%
6 Months
48.29%
12.4%
0.0%
1 Year
113.76%
4.6%
0.0%
3 Years
150.26%
15.7%
-21.9%

Highlights

Market Capitalization
3.3B
Book Value
$7.91
Earnings Per Share (EPS)
-3.69
Wall Street Target Price
57.92
Profit Margin
0.0%
Operating Margin TTM
-5547.17%
Return On Assets TTM
-28.18%
Return On Equity TTM
-50.16%
Revenue TTM
4.0M
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-125.5M
EBITDA
-221.5M
Diluted Eps TTM
-3.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.29
EPS Estimate Next Year
-3.54
EPS Estimate Current Quarter
-0.86
EPS Estimate Next Quarter
-0.87

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Crinetics Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 28.57%

Current $45.05
Target $57.92

Technicals Summary

Sell

Neutral

Buy

Crinetics Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
-5.82%
48.29%
113.76%
150.26%
70.37%
Moderna, Inc.
Moderna, Inc.
4.46%
44.76%
-17.31%
-40.7%
317.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.11%
12.56%
10.41%
82.28%
161.35%
Novo Nordisk A/s
Novo Nordisk A/s
0.6%
31.36%
53.28%
240.62%
422.33%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.58%
6.36%
13.86%
80.23%
127.58%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
NA
NA
NA
-3.29
-0.5
-0.28
NA
7.91
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Buy
$3.3B
70.37%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
317.84%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
161.35%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
422.33%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
127.58%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    6.86%
  • Driehaus Capital Management LLC

    6.47%
  • Point72 Asset Management, L.P.

    5.42%
  • FMR Inc

    5.19%
  • State Street Corporation

    4.57%
  • Vanguard Group Inc

    4.49%

Corporate Announcements

  • Crinetics Pharmaceuticals Inc Earnings

    Crinetics Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Organization
Crinetics Pharmaceuticals Inc
Employees
290
CEO
Dr. R. Scott Struthers Ph.D.
Industry
Health Technology

FAQs